| Previous Close | 22.95 |
| Open | 23.25 |
| Bid | 23.18 x 200 |
| Ask | 23.19 x 100 |
| Day's Range | 22.90 - 23.45 |
| 52 Week Range | 11.41 - 24.88 |
| Volume | 1,037,648 |
| Avg. Volume | 1,308,614 |
| Market Cap | 3.59B |
| Beta | 2.32 |
| PE Ratio (TTM) | -16.83 |
| EPS (TTM) | -1.37 |
| Earnings Date | Aug 1, 2017 - Aug 7, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.50 |
- Investor's Business Daily•23 hours ago
Could This Small Biotech Break Out On A Tie-Up With Eli Lilly?
Nektar neared a breakout on a deal with Lilly for a drug designed to fight autoimmune and inflammatory conditions.
- MarketWatch•yesterday
Eli Lilly will co-develop autoimmune disease therapy under $150 million deal with Nektar
The therapy could treat an underlying disease but is very early in development.
- TheStreet.com•yesterday
Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm
NeuroDerm, Novavax and Nektar Therapeutics were among the biotech stock movers in premarket trading on July 24.
